Pfizer names new SVP of clinical development and medical affairs for oncology

Dr Rothenberg comes to Pfizer from Vanderbilt where he was professor of medicine at the Vanderbilt University Medical Center and Ingram professor of cancer research at the Vanderbilt-Ingram Cancer Center.

In his new role, Dr Rothenberg will be responsible for overseeing clinical R&D activities as well as post-marketing evaluation and monitoring for all oncology products. He will also coordinate evaluation of anticancer compounds that emerge from Pfizer’s new biotechnology and bioinnovation center as well as evaluate potential in-licensed products from outside sources.

Garry Nicholson, senior vice president and general manager of the oncology business unit at Pfizer, said: “As we continue to progress in oncology, our primary focus is on advancing science so that we can address the unmet medical needs and bring medicines to patients faster.”